Reference Pricing Clauses In US COVID-19 Contracts Leave Drug Industry Vulnerable
Innovation and price controls can coexist in the United States, COVID-19 contracts show. But drug pricing experts also acknowledge the unique circumstances of COVID-19 could make such contracts hard to replicate and argue that reference-pricing strategies may have limited ability to lower prices.
You may also be interested in...
HHS Officials Raise Concerns About Pricing, Patent Restrictions for Medical Countermeasures
US FDA Commissioner and Health and Human Services Assistant Secretary for Preparedness and Response cautioned against changes to rewards for medical countermeasure developers in the next Pandemic and All-Hazards Preparedness Act reauthorization that might discourage biotech companies from working with the government.
Congress Eyes Vaccine Pricing With Spotlight On Pfizer As COVID Boosters Look More Likely
Senate hearing offers early signals that US lawmakers will be closely watching how COVID-19 vaccine pricing evolves. Biden team pledges to try to make contracting more transparent.
Happy Holidays: ‘Most Favored Nation’ Rule Effective Date Likely To Be Delayed
Either through the courts or a postponement by the Trump administration itself, the Medicare Part B rule seems destined to remain dormant instead of going into effect in January as scheduled.